AlphAIalphai — Financial news for AI agents
Stock TitanMAY 184 min read$MLYS

Lorundrostat Phase 3 data in uncontrolled blood pressure, CKD going to ESH 2026

Mineralys Therapeutics (Nasdaq: MLYS) announced it will present new Phase 3 data from its Launch-HTN trial for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The data, focusing on patients with uncontrolled hypertension and chronic kidney disease (CKD), will be presented orally on May 30, 2026, by Liffert Vogt, MD, PhD. The trial evaluated lorundrostat's efficacy and safety in adults whose blood pressure remained uncontrolled despite existing antihypertensive medications, with the primary endpoint being the change from baseline in systolic BP at six weeks.

Original reporting
Stock Titan
Published May 18, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 18, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Lorundrostat Phase 3 data in uncontrolled blood pressure, CKD going to ESH 2026 — source image
Source · Stock Titan
Decision brief

The 30-second read

$MLYSBullishHigh
01

Why it matters

Positive trial data could serve as a catalyst for stock appreciation; negative or inconclusive results may lead to declines.

02

Market read

The upcoming data presentation is a significant event that could influence investor sentiment and stock performance in the biotech sector.

03

What to watch

Potential regulatory hurdles or adverse safety data could negate positive trial results.

Timing: Immediate, as data presentation is scheduled for May 30, 2026.

Background

Mineralys Therapeutics is advancing lorundrostat, an investigational drug for hypertension and CKD, with upcoming presentation at ESH 2026.

Company-level read

Ticker impact

$MLYSBullishHigh confidence
Context

High relevance due to upcoming Phase 3 data presentation for lorundrostat, which may impact stock price.

Expected impact

Moderate increase in stock price expected around the presentation date, contingent on data outcomes.

Evidence & confidence

Phase 3 data presentation is a significant catalyst; positive preliminary results can boost investor confidence and stock valuation.

Market effects

Sector

Potential positive impact on the biotech and pharmaceutical sectors, especially companies involved in hypertension and CKD treatments.

Regional

Primarily affects European and North American markets where the presentation and company are based.

Global

Moderate; advances in hypertension treatments can influence global health markets.

Counterpoint

What could challenge this read

Data may not meet expectations, leading to a sell-off; overreliance on preliminary data can be risky.

Key entities

  • Company
    Mineralys Therapeutics

    Biotech company developing lorundrostat for hypertension and CKD.

  • Drug
    Lorundrostat

    Investigational medication targeting uncontrolled blood pressure in CKD patients.

  • Presenter
    Liffert Vogt, MD, PhD

    Researcher presenting the trial data at ESH 2026.

Read at source← All news

Related articles

JUN 3
$MLYSMedAI 9/10

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Mineralys Therapeutics (NASDAQ: MLYS) said it will repurchase all future royalty payments to Tanabe Pharma for lorundrostat under their license agreement for $200 million upfront and up to $100 million tied to commercial milestones. The company also entered a $500 million senior secured term loan with Pharmakon Advisors, with $100 million funded at closing, and priced an underwritten ~$150 million common stock offering.

manilatimes.net4 min
JUN 1
$MLYSMedAI 9/10

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Velan Capital sold 140,000 shares of Mineralys Therapeutics (MLYS), worth about $4.1 million, according to the report. Mineralys’ drug lorundrostat, an aldosterone synthase inhibitor for hypertension, is under FDA review for its first combination therapy application, with a decision expected by Dec. 22, 2026. Mineralys reported a $39.3 million Q1 loss and $646 million cash at March-end.

finance.yahoo.com4 min
AUG 8
$NOKMed

Nokia’s (NOK) AI Network Bet Gets A Taiwan Proving Ground

Nokia (NOK) said it signed a 5G expansion agreement with Taiwan Mobile on July 14 to deploy its AirScale portfolio and AI-driven network software. The deal covers four AI applications, including predictive analytics, SON automation, baseband and radio upgrades, energy management, and self-healing. Nokia cites Aetha data on AI traffic growth and expects AI-RAN spectral efficiency to rise from 20% to 50% next year and 100% by 2028.

yahoo.com4 min